Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Medicus Pharma Ltd., a Nasdaq-listed biotech company, announced its participation in the 2026 Bio International Conference to present advancements in its clinical development programs for SkinJect®, an innovative treatment for basal cell carcinoma and Gorlin Syndrome, and Teverelix®, a next-generation GnRH antagonist targeting prostate cancer, acut…